Hepatitis B and C viruses, human T-cell lymphotrophic virus (HTLV I, II), and leukemias. A case control study (Meeting abstract).

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Hepatitis B and C viruses, human T-cell lymphotrophic virus (HTLV I, II), and leukemias. A case control study (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 36:A1666 1995. Unique Identifier : AIDSLINE ICDB/95609441
Gentile G; Mele A; Monarca B; Vitale A; Pulsoni A; Visani G; Castelli G; Rapicetta M; Verani P; Martino P; et al; Istituto Superiore di Sanita, Rome, Italy

Abstract: We investigated the relationships between acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia and refractory anemia with excess of blasts and antibodies to human T lymphotropic (HTLV) virus type I and II and hepatitis B and C viruses in a multicenter case control study on risk factors for acute leukemias. 431 cases and 862 controls aged 15 years or older were recruited in three hospitals. All cases and controls were negative for HTLV-I antibodies; whereas one case and one control were found positive for HTLV-II antibodies. A significant association was found between Hbsag and pre-acute leukemias (chronic myeloid leukemia and anemia with excess of blasts) (odds ratio [OR], 2.9; 95% confidence interval [CI], 1.0-8.5). A slight but not significant association was present between acute myeloid leukemia, acute lymphocytic leukemia, anemia with excess of blasts and anti-HCV.

Keywords: Anemia, Refractory, with Excess of Blasts/*IMMUNOLOGY/VIROLOGY Antibodies, Viral/*BLOOD Case-Control Studies Hepatitis B Virus/IMMUNOLOGY Hepatitis C Viruses/IMMUNOLOGY Human HTLV-I/IMMUNOLOGY HTLV-II/IMMUNOLOGY Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/*IMMUNOLOGY/ VIROLOGY Leukemia, Lymphocytic, Acute/*IMMUNOLOGY/VIROLOGY Leukemia, Myelocytic, Acute/*IMMUNOLOGY/VIROLOGY Leukemia, Myeloid, Chronic/*IMMUNOLOGY/VIROLOGY Leukemia, T-Cell, HTLV-II-Associated/*IMMUNOLOGY/VIROLOGY Risk Factors ABSTRACT MULTICENTER STUDY

$KWDanemia,refractory,withexcessofblasts/$
951130
M95B0951

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .